AU9084191A - Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke - Google Patents

Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke

Info

Publication number
AU9084191A
AU9084191A AU90841/91A AU9084191A AU9084191A AU 9084191 A AU9084191 A AU 9084191A AU 90841/91 A AU90841/91 A AU 90841/91A AU 9084191 A AU9084191 A AU 9084191A AU 9084191 A AU9084191 A AU 9084191A
Authority
AU
Australia
Prior art keywords
angiotensin
treatment
receptor antagonists
hemorragic
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU90841/91A
Other languages
English (en)
Inventor
James Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU9084191A publication Critical patent/AU9084191A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU90841/91A 1990-12-14 1991-12-12 Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke Abandoned AU9084191A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027199A GB9027199D0 (en) 1990-12-14 1990-12-14 Medicaments
GB9027199 1990-12-14

Publications (1)

Publication Number Publication Date
AU9084191A true AU9084191A (en) 1992-07-08

Family

ID=10687035

Family Applications (1)

Application Number Title Priority Date Filing Date
AU90841/91A Abandoned AU9084191A (en) 1990-12-14 1991-12-12 Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke

Country Status (6)

Country Link
EP (1) EP0561977B1 (ja)
JP (1) JPH06503558A (ja)
AU (1) AU9084191A (ja)
DE (1) DE69133390T2 (ja)
GB (1) GB9027199D0 (ja)
WO (1) WO1992010188A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
HUP0003982A3 (en) 1997-10-17 2002-01-28 Eurogene Ltd The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
EP1450793A2 (de) * 2001-11-23 2004-09-01 Solvay Pharmaceuticals GmbH Hypertoniebehandlung während der akuten phase des schlaganfalls
EP1865945A4 (en) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
ATE250587T1 (de) * 1989-06-14 2003-10-15 Smithkline Beecham Corp Imidazoalkensäure
CA2018443A1 (en) * 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
GB9027199D0 (en) 1991-02-06
DE69133390D1 (de) 2004-07-01
WO1992010188A1 (en) 1992-06-25
DE69133390T2 (de) 2005-06-02
JPH06503558A (ja) 1994-04-21
EP0561977B1 (en) 2004-05-26
EP0561977A1 (en) 1993-09-29

Similar Documents

Publication Publication Date Title
AU8374491A (en) Angiotensin II receptor antagonists
AU9064991A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy
HK1005801A1 (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
HU9402486D0 (en) Sulfonamide endotheline antagonists
HU9301603D0 (en) Angiotensine 11 antagonists
AU6166394A (en) Bath mat for use in bathing others
IL109094A0 (en) Human tnf muteins
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU9058591A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic nephropathy
AU3276293A (en) Angiotensin II receptor antagonists
IE900957L (en) Dihydropyrimidine antiallergy agents
AU9084191A (en) Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke
AU8534291A (en) Renal-selective angiotensin ii antagonists for treatment of hypertension
AU9069191A (en) Use of angiotensin ii receptor antagonists in the prevention of restinosis
AU9052991A (en) Use of angiotensin ii antagonist in the treatment of infarction
AU9065291A (en) Use of angiotensin ii receptor antagonists in the treatment of macular degeneration
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
EP0547178A4 (en) Novel cholecystokinin antagonists, their preparation and therapeutic use
AU4163793A (en) Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease
AU9064191A (en) Use of angiotensin ii receptor antagonists in the treatment of atheroma
AU9081691A (en) Use of angiotensin ii antagonists in the treatment of angina pectoris
AU9071291A (en) Use of angiotensin ii antagonists in the treatment of left ventricular hypertrophy
AU4585993A (en) Use of angiotensin ii antagonists for the treatment of hyperlipidaeme
HUP9902059A3 (en) Hyaluronic acid receptors binding agents and the use thereof
ZA943549B (en) Cell surface protein expressed on human cortical thymocyte and their use